Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

IGM Biosciences Q2 EPS $(1.16) Down From $(0.62) YoY

IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(1.16) per share. This is a 87.1 percent decrease over losses of $(0.62) per share from the same period last year.

byBenzinga Newsdesk

August 9, 2021

1 minute read

IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(1.16) per share. This is a 87.1 percent decrease over losses of $(0.62) per share from the same period last year.

Keybanc Maintains Overweight on SM Energy, Lowers Price Target to $56

By Benzinga Newsdesk

Today, 4:42 AM

Keybanc analyst Tim Rezvan maintains SM Energy (NYSE:SM) with a Overweight and lowers the price target from $64 to $56.

Canaccord Cuts Virgin Galactic Price Target By 18%, Remains Bullish

By Akanksha Bakshi

Today, 4:42 AM

Canaccord Genuity analyst Austin Moeller lowered Virgin Galactic Holdings Inc (NYSE: SPCE)

SPCE

B. Riley Securities Maintains Buy on Lululemon Athletica, Lowers Price Target to $370

By Benzinga Newsdesk

Today, 4:42 AM

B. Riley Securities analyst Susan Anderson maintains Lululemon Athletica (NASDAQ:LULU) with a Buy and lowers the price target from $374 to $370.

LULU

Editas Medicine Q4 EPS $(0.88) Misses $(0.80) Estimate, Sales $6.54M Beat $3.26M Estimate

By Benzinga Newsdesk

Today, 4:42 AM

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.80) by 10 percent. This is a 44.26 percent decrease over losses of $(0.61) per share from

EDIT

IGM Biosciences Q2 EPS $(1.16) Down From $(0.62) YoY

Related Posts

Keybanc Maintains Overweight on SM Energy, Lowers Price Target to $56

Canaccord Cuts Virgin Galactic Price Target By 18%, Remains Bullish

B. Riley Securities Maintains Buy on Lululemon Athletica, Lowers Price Target to $370

Editas Medicine Q4 EPS $(0.88) Misses $(0.80) Estimate, Sales $6.54M Beat $3.26M Estimate